KF
NTLA icon

Krilogy Financial’s Intellia Therapeutics NTLA Stock Holding History

Krilogy Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54,673
Closed -$1.22M – 230
2024
Q2 		$1.22M Buy
54,673
+4,556
+9% +$108K 0.09% 147
2024
Q1 		$1.38M Buy
50,117
+27,613
+123% +$767K 0.11% 144
2023
Q4 		$686K Buy
+22,504
New +$647K 0.06% 168
2018
Q1 		– Sell
-200
Closed -$4K – 800
2017
Q4 		$4K Buy
+200
New +$4.62K ﹤0.01% 635
2017
Q3 		– Sell
-300
Closed -$5K – 833
2017
Q2 		$5K Buy
+300
New +$4.19K ﹤0.01% 592

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krilogy Financial's NTLA Position: Q3 2024 in Review

Krilogy Financial sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 54,673 shares — an estimated $1.22M sold.

Krilogy Financial first reported a position in NTLA in Q2 2017 and held it in 5 quarters. The position peaked at $1.38M in Q1 2024. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Krilogy Financial reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Krilogy Financial sold 54,673 Intellia Therapeutics shares in Q3 2024, an estimated $1.22M.
  • Krilogy Financial first reported a position in Intellia Therapeutics in Q2 2017 and held it in 5 quarters.
  • Krilogy Financial's Intellia Therapeutics position peaked at $1.38M in Q1 2024.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Krilogy Financial's 13F filing for Q3 2024, filed 15 Oct 2024.